Elsevier

Drug Resistance Updates

Volume 5, Issues 3–4, June–August 2002, Pages 162-175
Drug Resistance Updates

Retinoids in combination therapies for the treatment of cancer: mechanisms and perspectives

https://doi.org/10.1016/S1368-7646(02)00050-XGet rights and content

Abstract

Retinoid derivatives have been of special interest in cancer research because of their antiproliferative and differentiation-inducing activities in premalignant and malignant cells. Some retinoids are clinically effective in cancer therapy and prevention, and all-trans-retinoic acid is being used for the treatment of acute promyelocytic leukemia. Unfortunately, classical retinoids are not effective against most advanced solid tumors and cause undesirable side effects, which have limited the full development of retinoids as chemopreventive and chemotherapeutic drugs. The recent identification of selective retinoid derivatives capable of inducing apoptosis and their combination with other anticancer therapies promises a more effective and less toxic manner to the successful use of retinoids in cancer therapy.

Introduction

Retinoids are derivatives of Vitamin A (retinol), which is essential for fertility and vision and plays a critical role in important biological functions including cell growth and differentiation, development, metabolism, and immunity. All-trans-retinoic acid (atRA) and 9-cis-RA are the active metabolites that regulate expression of target genes through binding to and activation of the nuclear retinoid receptors: atRA receptors (RARs) and Retinoid X receptors (RXRs). Retinoids inhibit the proliferation of cancer cells and induce cell differentiation of malignant cells, making these compounds one of the most prominent groups of chemopreventive agents.

Retinoid use in cancer therapy has been extensively studied over the years and almost certainly the best example is represented by the successful use of atRA in the treatment of acute promyelocytic leukemia (APL), while 13-cis-RA is effective against juvenile chronic myelogenous leukemia and mycosis fungoides (cutaneous T-cell lymphoma) in clinical studies. The combination of 13-cis-RA with interferon-α-2a (IFNα) has been shown to be effective against squamous cell carcinomas of skin and cervix. However, natural retinoids have shown limited efficacy in most solid malignancies. Furthermore, the reversible effect of retinoids requires prolonged treatments that are often associated with toxicity and the development of retinoid resistance. Although many of the factors influencing resistance are not well understood, aberrant expression and function of the retinoid-binding proteins or the nuclear retinoid receptors, as well as defects in retinoid metabolism, may result in sub-optimal clinical results. Most classical retinoids are also teratogenic and cause birth defects, raising major concerns for pregnant women. Because of the limited clinical efficacy, large efforts have been devoted during the last two decades to the synthesis of retinoid derivatives with selective activities, in an attempt to improve anticancer activity and to separate beneficial from toxic effects.

A major breakthrough in retinoid research was the isolation of the nuclear retinoid receptors and the elucidation of the mechanism of retinoid action. This allowed the identification of retinoids that selectively activate a subset of receptors and elicit a restricted biological response. Novel selective retinoids have become very promising as anticancer agents, either alone or in combination therapies. Indeed, some of these synthetic compounds or retinoid-related molecules (RRMs), which are selective for RARγ or inhibit receptor-mediated transcriptional activity (antagonists), have recently been shown to be potent inducers of apoptosis in cancer cells in vitro and to be effective against the growth of solid tumors in animal models with no overt signs of toxicity (Lu et al., 1997; Fanjul et al., 1998). A large body of literature has been produced over the years on clinical and preclinical studies using natural retinoids and related compounds (classical retinoids) alone or in combination therapies for the prevention and treatment of cancer. Many of the studies have recently been reviewed (Lotan and Hong, 2001; Nason-Burchenal and Dmitrovsky, 1999; Smith et al., 1992). We will focus on the most recent studies describing the use of retinoids in combination therapies for the treatment of cancer and the mechanism of apoptosis induction by novel selective RRMs with potential clinical applications, including a brief description of the mechanism of action of the nuclear retinoid receptors and selective retinoids.

Section snippets

Nuclear retinoid receptors mediate retinoid signals: the search for selective retinoids

Retinoid signals are mediated by the nuclear retinoid receptors, which belong to the nuclear hormone receptor superfamily of transcription factors. This includes receptors for steroid hormones, RA, thyroid hormone and Vitamin D3 (Piedrafita and Pfahl, 1999). In addition, a fast-growing group of orphan receptors has been described and a subset of these were found to respond to a variety of ligands (reviewed in the reference (Chawla et al., 2001)). The six known retinoid receptors (RARα, -β, -γ

Recent progress using retinoids in combination therapies: in vitro studies

Numerous studies in vitro and in animal models have demonstrated a synergistic action of retinoids in combination with other chemotherapeutic agents. Perhaps the most extensively analyzed combination is that of retinoids with interferons, both in vitro and in clinical trials. Mixed results have been obtained, depending on the type of tumor and even on different cell lines of the same type of cancer. Most studies have utilized atRA or 13-cis-RA with IFNα and have shown positive results in vitro

Retinoids in combination therapies: clinical trials

Retinoids have been tested in numerous clinical trials for the prevention of cancer based on their ability to induce cell differentiation and inhibit tumor growth in animal models. Studies were initiated with atRA (tretinoin) and 13-cis-RA (isotretinoin) (Table 1) and more recently the RARγ-selective compound 4-HPR was used alone or in combination with tamoxifen to prevent development of mammary tumors. Another promising compound, LGD 1069, is also effective in the chemoprevention of breast

Induction of apoptosis by selective RRMs: a novel RAR-independent mechanism of retinoid action

Three types of selective retinoids that induce apoptosis in cancer cells are particularly interesting for clinical evaluation. 4-HPR, which is already being tested in clinical trials under the name of fenretinide shows significant activity as chemopreventive agent and was found to induce apoptosis in HL-60 cells independently of the retinoid receptors (Delia et al., 1993). Production of reactive oxygen species occurred concomitant to 4-HPR treatment and antioxidants inhibited 4-HPR-induced

Perspectives

Although some retinoids are effective in single therapies for the prevention and treatment of certain malignancies, including skin cancer, APL, CTCL, and oral leukoplakia, most solid tumors are untreatable with currently available retinoids. Retinoids in combination with a variety of commonly used therapeutic agents have shown synergistic activities against the growth of different types of cancer cell lines in vitro. Many of those combinations were also effective in animal models and showed

Acknowledgements

Work in our laboratory is supported by grants from the NIH and the California Cancer Research Program. Retinoids used in our studies were provided by Maxia Pharmaceuticals and Galderma Research Inc.

References (126)

  • D.J. Mangelsdorf et al.

    The RXR heterodimers and orphan receptors

    Cell

    (1995)
  • L.S. Massad et al.

    Interferon-alpha and all-trans-retinoic acid reversibly inhibit the in vitro proliferation of cell lines derived from cervical cancers

    Gynecol. Oncol.

    (1996)
  • K. Maundrell et al.

    Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1

    J. Biol. Chem.

    (1997)
  • N.J. McKenna et al.

    Combinatorial control of gene expression by nuclear receptors and coregulators

    Cell

    (2002)
  • W.H. Miller et al.

    A phase I–II study of 9-cis-retionic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study

    Ann. Oncol.

    (2000)
  • L. Mologni et al.

    The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2- naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases

    Blood

    (1999)
  • S.Y. Na et al.

    Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFkappaB

    J. Biol. Chem.

    (1999)
  • C. Niu et al.

    Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients

    Blood

    (1999)
  • M.A. Sanz et al.

    A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group

    Blood

    (1999)
  • C.A. Schmitt et al.

    Apoptosis is critical for drug response in vivo

    Drug Resistance Updates

    (2001)
  • Z.X. Shen et al.

    Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients

    Blood

    (1997)
  • A.K. Shiau et al.

    The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

    Cell

    (1998)
  • L. Altucci et al.

    Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL

    Nat. Med.

    (2001)
  • N. Asou et al.

    Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG)

    Cancer Chemother. Pharmacol.

    (2001)
  • Beard, R.L., Chandraratna, R.A.S., 1999. RAR-selective ligands: receptor subtype and function selectivity. In: Nau, H.,...
  • A.S. Belzacq et al.

    Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437

    Oncogene

    (2001)
  • M. Benthin et al.

    13cis- and all-trans-retinoic acid have antiproliferative effects on CML cells and render IFN alpha antiproliferative potency after combined treatment in vitro

    Cancer Biother. Radiopharm.

    (2001)
  • A. Bernard et al.

    Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor γ

    Biochem. Biophys. Res. Commun.

    (1992)
  • E.D. Bischoff et al.

    Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma

    Cancer Res.

    (1998)
  • D.K. Biswas et al.

    The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers

    Proc. Natl. Acad. Sci. USA

    (2001)
  • A.M. Brzozowski et al.

    Molecular basis of agonism and antagonism in the oestrogen receptor

    Nature

    (1997)
  • M.J. Campbell et al.

    Synergistic inhibition of prostate cancer cell lines by a 19-nor hexafluoride Vitamin D3 analogue and anti-activator protein 1 retinoid

    Br. J. Cancer

    (1999)
  • A. Chawla et al.

    Nuclear receptors and lipid physiology: opening the X-files

    Science

    (2001)
  • Z. Chen et al.

    Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia

    EMBO J.

    (1993)
  • Z. Chen et al.

    Combination of all-trans-retinoic acid with butyric acid and its prodrugs markedly enhancing differentiation of human acute promyelocytic leukemia NB4 cells

    Chin. Med. J. Engl.

    (1999)
  • D.C. Coffey et al.

    The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans-retinoic acid

    Cancer Res.

    (2001)
  • M. Crettaz et al.

    Ligand specificities of recombinant retinoic acid receptors RARα and RARβ

    Biochem. J.

    (1990)
  • H. de The et al.

    The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor a gene to a novel transcribed locus

    Nature

    (1990)
  • D. Delia et al.

    N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid

    Cancer Res.

    (1993)
  • D. Delia et al.

    Role of antioxidants and intracellular free radicals in retinamide-induced cell death

    Carcinogenesis

    (1997)
  • K. Demary et al.

    Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells

    Cancer Lett.

    (2001)
  • R.O. Dillman et al.

    Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma

    Neurooncology

    (2001)
  • E. Elstner et al.

    Combination of a potent 20-epi-Vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells

    Cancer Res.

    (1996)
  • E. Elstner et al.

    Novel 20-epi-Vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells

    Prostate

    (1999)
  • A. Fanjul et al.

    A novel class of retinoids with selective anti-AP-1 activity exhibit anti-proliferative activity

    Nature

    (1994)
  • A.N. Fanjul et al.

    Apoptosis induction and potent antiestrogen receptor-negative breast cancer activity in vivo by a retinoid antagonist

    Cancer Res.

    (1998)
  • F.F. Ferrara et al.

    Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia

    Cancer Res.

    (2001)
  • A.C. Ferrari et al.

    13-cis-retionic acid and complete androgen blockade in advanced hormone-naive prostate cancer patients: report of a phase II randomized study

    J. Clin. Oncol.

    (2002)
  • J.A. Fontana et al.

    Overexpression of bcl-2 or bcl-XL fails to inhibit apoptosis mediated by a novel retinoid

    Oncol. Res

    (1998)
  • C.K. Glass et al.

    The coregulator exchange in transcriptional functions of nuclear receptors

    Genes Dev.

    (2000 Jan 15)
  • Cited by (44)

    • Pharmacokinetics of a paclitaxel-loaded low molecular weight heparin-all-trans-retinoid acid conjugate ternary nanoparticulate drug delivery system

      2012, Biomaterials
      Citation Excerpt :

      PTX, a potent promoter of microtubulin polymerization, is one of the most effective drugs for treatment of several solid tumor malignancies [17]. On the other hand, ATRA, an active metabolic of vitamin A, inhibits the proliferation of cancer cells and induce cell differentiation of malignant cells [18]. It has been reported that combination of PTX with ATRA caused regression of tumor by down regulation of survival factors and activation of mitochondria-dependent multiple molecular mechanisms for apoptosis [19].

    • Highly twisted adamantyl arotinoids: Synthesis, antiproliferative effects and RXR transactivation profiles

      2009, European Journal of Medicinal Chemistry
      Citation Excerpt :

      This exposes a LXXLL motif necessary for the recruitment of chromatin-modifying co-activators and the RNA polymerase II transcriptional machinery to initiate transcription (see [5,6] and references therein). Despite their promising activity in vitro, most natural and synthetic retinoid analogs exhibit significant toxicity that has limited their oncological therapeutic use [7]. All-trans-retinoic acid (atRA) is used as a differentiation agent against acute promyelocytic leukaemia [8], whereas the synthetic RXR agonist LGD1069 (Targretin®) has been approved for the treatment of cutaneous T cell lymphoma [9] and is being clinically evaluated against lung and breast cancers [10].

    • Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death

      2008, Blood
      Citation Excerpt :

      Despite recent achievements,1,2 progress in therapy is slow for most malignancies, including acute myelogenous leukemia (AML).3

    • Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models

      2007, Annals of Oncology
      Citation Excerpt :

      Antitumor activity of a number of adamantyl retinoids, including CD437, MX3350-1 and ST1926, has been described in human tumor models of various histotypes [3]. Thus, these retinoid-related molecules represent an emerging group of promising antitumor agents endowed with remarkable apoptotic activity against leukemia cells and cells from various solid tumors [3, 16]. ST1926, one of the most promising compounds of this series, was shown to induce a high level of apoptosis in ovarian carcinoma cells at sub-micromolar concentrations [7].

    • Retinoic acid attenuates promyelocytic leukemia protein-induced cell death in breast cancer cells by activation of the ubiquitin-proteasome pathway

      2007, Cancer Letters
      Citation Excerpt :

      During carcinogenesis, an intrinsic resistance to retinoids develops in solid tumors. Clinical strategies to overcome this resistance include efforts to reduce the toxicity of RAs and to develop effective combined therapies [21]. In chemopreventive studies for breast cancer in the murine model, the combined therapy of retinoids plus a selective estrogen receptor modulator (SERM) was more effective than a single-agent therapy [22].

    View all citing articles on Scopus
    View full text